[go: up one dir, main page]

CN1077109C - S型2－取代羟基－2－中氮茚基丁酸酯化合物和其制备方法 - Google Patents

S型2－取代羟基－2－中氮茚基丁酸酯化合物和其制备方法 Download PDF

Info

Publication number
CN1077109C
CN1077109C CN97122529A CN97122529A CN1077109C CN 1077109 C CN1077109 C CN 1077109C CN 97122529 A CN97122529 A CN 97122529A CN 97122529 A CN97122529 A CN 97122529A CN 1077109 C CN1077109 C CN 1077109C
Authority
CN
China
Prior art keywords
compound
group
residue
indolizine
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN97122529A
Other languages
English (en)
Chinese (zh)
Other versions
CN1183414A (zh
Inventor
川口隆行
野村纯宏
辻原健二
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Seiyaku Co Ltd
Original Assignee
Tanabe Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co Ltd filed Critical Tanabe Seiyaku Co Ltd
Publication of CN1183414A publication Critical patent/CN1183414A/zh
Application granted granted Critical
Publication of CN1077109C publication Critical patent/CN1077109C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • G—PHYSICS
    • G02—OPTICS
    • G02F—OPTICAL DEVICES OR ARRANGEMENTS FOR THE CONTROL OF LIGHT BY MODIFICATION OF THE OPTICAL PROPERTIES OF THE MEDIA OF THE ELEMENTS INVOLVED THEREIN; NON-LINEAR OPTICS; FREQUENCY-CHANGING OF LIGHT; OPTICAL LOGIC ELEMENTS; OPTICAL ANALOGUE/DIGITAL CONVERTERS
    • G02F1/00—Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics
    • G02F1/01—Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour 
    • G02F1/13—Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour  based on liquid crystals, e.g. single liquid crystal display cells
    • G02F1/133—Constructional arrangements; Operation of liquid crystal cells; Circuit arrangements
    • G02F1/1333—Constructional arrangements; Manufacturing methods
    • G02F1/1345—Conductors connecting electrodes to cell terminals
    • G02F1/13452—Conductors connecting driver circuitry and terminals of panels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • G—PHYSICS
    • G02—OPTICS
    • G02F—OPTICAL DEVICES OR ARRANGEMENTS FOR THE CONTROL OF LIGHT BY MODIFICATION OF THE OPTICAL PROPERTIES OF THE MEDIA OF THE ELEMENTS INVOLVED THEREIN; NON-LINEAR OPTICS; FREQUENCY-CHANGING OF LIGHT; OPTICAL LOGIC ELEMENTS; OPTICAL ANALOGUE/DIGITAL CONVERTERS
    • G02F1/00—Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics
    • G02F1/01—Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour 
    • G02F1/13—Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour  based on liquid crystals, e.g. single liquid crystal display cells
    • G02F1/1303—Apparatus specially adapted to the manufacture of LCDs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Nonlinear Science (AREA)
  • Optics & Photonics (AREA)
  • Health & Medical Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Manufacturing & Machinery (AREA)
  • Mathematical Physics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN97122529A 1996-10-30 1997-10-30 S型2－取代羟基－2－中氮茚基丁酸酯化合物和其制备方法 Expired - Fee Related CN1077109C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP288074/96 1996-10-30
JP288074/1996 1996-10-30
JP28807496 1996-10-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB011109580A Division CN100473654C (zh) 1996-10-30 1997-10-30 S型4-取代羟基吡喃并吲哚哩啶化合物和其衍生物以及其制备方法

Publications (2)

Publication Number Publication Date
CN1183414A CN1183414A (zh) 1998-06-03
CN1077109C true CN1077109C (zh) 2002-01-02

Family

ID=17725479

Family Applications (3)

Application Number Title Priority Date Filing Date
CN97122529A Expired - Fee Related CN1077109C (zh) 1996-10-30 1997-10-30 S型2－取代羟基－2－中氮茚基丁酸酯化合物和其制备方法
CNB011109580A Expired - Fee Related CN100473654C (zh) 1996-10-30 1997-10-30 S型4-取代羟基吡喃并吲哚哩啶化合物和其衍生物以及其制备方法
CNB2006101011920A Expired - Fee Related CN100528879C (zh) 1996-10-30 1997-10-30 S型4-取代羟基吡喃并吲哚哩啶化合物和其衍生物以及其制备方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CNB011109580A Expired - Fee Related CN100473654C (zh) 1996-10-30 1997-10-30 S型4-取代羟基吡喃并吲哚哩啶化合物和其衍生物以及其制备方法
CNB2006101011920A Expired - Fee Related CN100528879C (zh) 1996-10-30 1997-10-30 S型4-取代羟基吡喃并吲哚哩啶化合物和其衍生物以及其制备方法

Country Status (14)

Country Link
US (7) US5932732A (fr)
EP (3) EP1236728B1 (fr)
KR (5) KR100474496B1 (fr)
CN (3) CN1077109C (fr)
AT (2) ATE247120T1 (fr)
CA (2) CA2533685C (fr)
DE (2) DE69736308T2 (fr)
DK (2) DK1236728T3 (fr)
ES (2) ES2267879T3 (fr)
HK (2) HK1050356B (fr)
ID (1) ID18747A (fr)
PT (2) PT845464E (fr)
SG (4) SG116433A1 (fr)
TW (1) TW464652B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG116433A1 (en) * 1996-10-30 2005-11-28 Tanabe Seiyaku Co S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof.
AU2002246510B2 (en) 2000-11-09 2007-09-20 Neopharm, Inc. SN-38 lipid complexes and methods of use
US20090137816A1 (en) * 2000-12-15 2009-05-28 Kurt Baum Process for the manufacture of diaminofurazan
US6350756B1 (en) 2001-01-18 2002-02-26 California Pacific Medical Center Camptothecin derivatives
AR035684A1 (es) 2001-02-21 2004-06-23 Yakult Honsha Kk Procedimiento para preparar 2'-amino-5'-hidroxipropiofenona, uso de la misma para la preparacion de analogos de camptotecina, procedimiento para prepararlos, compuestos intermediarios, procedimiento para preparar una cetona triciclica utilizada en la sintesis de analogos de camptotecina
CN101337900B (zh) * 2001-02-21 2013-12-18 株式会社雅库路特本社 喜树碱相关化合物的合成方法
US6855720B2 (en) 2001-03-01 2005-02-15 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US6403604B1 (en) 2001-03-01 2002-06-11 California Pacific Medical Center Nitrogen-based camptothecin derivatives
WO2003030864A1 (fr) * 2001-05-29 2003-04-17 Neopharm, Inc. Formulation liposomale d'irinotecan
AU2003243380A1 (en) * 2002-06-03 2003-12-19 California Pacific Medical Center Nitrogen-based homo-camptothecin derivatives
US20040034050A1 (en) * 2002-06-03 2004-02-19 Yang Li-Xi Homo-camptothecin derivatives
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
WO2004035032A2 (fr) * 2002-08-20 2004-04-29 Neopharm, Inc. Formulation de sn-38 a base de lipides pharmaceutiquement actifs
JP4433918B2 (ja) * 2004-07-15 2010-03-17 コニカミノルタエムジー株式会社 画像形成方法
KR100651728B1 (ko) * 2004-11-10 2006-12-06 한국전자통신연구원 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
CN100390177C (zh) * 2004-11-25 2008-05-28 复旦大学 6-氰基-7-甲基-1,1-(2,2-二甲基-1,3-亚丙二氧基)-5-氧-1,2,3,5-四氢吲哚哩啶(i)的制备方法
EP1910269B1 (fr) * 2005-08-03 2013-09-18 Avra Laboratories PVT. Ltd. Procede de synthese d'intermediaires cles pour la production de derives de camptothecine
US7875602B2 (en) * 2005-10-21 2011-01-25 Sutter West Bay Hospitals Camptothecin derivatives as chemoradiosensitizing agents
CN104341429B (zh) * 2013-07-29 2016-08-10 北大方正集团有限公司 (s)-喜树碱中间体的制备方法及(s)-喜树碱的制备方法
AR114473A1 (es) * 2018-04-06 2020-09-09 Seattle Genetics Inc Conjugados péptido-camptotecina
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
CN113041841B (zh) * 2021-03-22 2022-07-12 万华化学集团股份有限公司 一种抗污染浓水隔网的制备方法及应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399282A (en) * 1979-07-10 1983-08-16 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives
JPS5711607A (en) * 1980-06-25 1982-01-21 Tokyo Shibaura Electric Co Movable shelf control apparatus
JPS57116074A (en) 1981-01-09 1982-07-19 Yakult Honsha Co Ltd Novel camptothecin derivative and its preparation
US4473692A (en) * 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
EP0220601B1 (fr) * 1985-10-21 1991-12-11 Daiichi Seiyaku Co., Ltd. Dérivés de la pyranoindolizine et procédé de préparation
US4981968A (en) * 1987-03-31 1991-01-01 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US5053512A (en) * 1987-04-14 1991-10-01 Research Triangle Institute Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives
US5244903A (en) * 1987-03-31 1993-09-14 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US5122606A (en) * 1987-04-14 1992-06-16 Research Triangle Institute 10,11-methylenedioxy camptothecins
US4939255A (en) * 1987-06-24 1990-07-03 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic camptothecin derivatives
US4943579A (en) 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
JPH0615547B2 (ja) * 1988-01-20 1994-03-02 株式会社ヤクルト本社 新規なカンプトテシン誘導体
JP2524803B2 (ja) * 1988-03-29 1996-08-14 株式会社ヤクルト本社 新規なカンプトテシン誘導体およびその製造法
DE69033880T2 (de) * 1989-09-15 2002-06-06 Research Triangle Institute, Research Triangle Park Verfahren zur herstellung von 10,11-Methylendioxy-20(RS)-Camptothecin und 10,11-Methylendioxy-20(S)-Camptothecin-Analog
TW201303B (fr) * 1990-07-05 1993-03-01 Hoffmann La Roche
HU213136B (en) * 1990-08-14 1997-02-28 Kyorin Seiyaku Kk Process for producing fluoroethyl camptothecin derivatives and pharmaceutical compositions containing them
JP2923692B2 (ja) * 1990-11-30 1999-07-26 第一製薬株式会社 酵素による光学分割法
JP2887524B2 (ja) * 1990-11-30 1999-04-26 第一製薬株式会社 微生物による光学分割法
JPH04210675A (ja) * 1990-12-13 1992-07-31 Otsuka Pharmaceut Co Ltd ベンゼン誘導体
DK0540099T3 (da) * 1991-10-29 1996-06-17 Glaxo Wellcome Inc Vandopløselige camptothecinderivater
CA2087898A1 (fr) * 1992-01-24 1993-07-25 Hiroshi Akimoto Composes heterocycliques condenses, leur preparation et leur utilisation
WO1993016698A1 (fr) * 1992-02-21 1993-09-02 Smithkline Beecham Corporation FURO[3',4':6,7]INDOLIZINO[1,2-b]QUINOLINONES SUBSTITUEES
JP3126798B2 (ja) * 1992-03-31 2001-01-22 第一製薬株式会社 光学活性インドリジン誘導体及びその製法
JP3126799B2 (ja) * 1992-03-31 2001-01-22 第一製薬株式会社 光学活性カンプトテシン誘導体及びその製法
JP3359955B2 (ja) * 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
IS4152A (is) * 1993-04-29 1994-10-30 Glaxo Inc. Vatnsuppleysanlegar Camptothecin afleiður og aðferð til framleiðslu þeirra
JPH07101956A (ja) * 1993-10-05 1995-04-18 Tanabe Seiyaku Co Ltd ヒドロキシカンプトテシン化合物の製法
KR960029336A (ko) * 1995-01-09 1996-08-17 김충환 캄토테신 유도체, 그의 제조 방법 및 이를 함유하는 항암제
IL117684A (en) * 1995-04-07 2002-02-10 Pharmacia & Upjohn Inc Intermediates and Process for Production of History of Kempotocin (CPT-11) and Related Compounds
US5728712A (en) * 1995-05-19 1998-03-17 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
DK0861236T4 (da) * 1995-11-13 2006-12-18 Sanofi Aventis Deutschland Cykliske og heterocykliske N-substituerede alphaiminohydroxam- og carboxylsyrer
WO1997019085A1 (fr) 1995-11-22 1997-05-29 Research Triangle Institute Composes de camptothecine a proprietes combinees d'inhibition de la topoisomerase i et d'alkylation de l'adn
CA2192725C (fr) * 1995-12-28 2004-04-20 Kenji Tsujihara Derives de la camptothecine
US5731316A (en) 1996-01-30 1998-03-24 The Stehlin Foundation For Cancer Research Derivatives of camptothecin and methods of treating cancer using these derivatives
SG116433A1 (en) * 1996-10-30 2005-11-28 Tanabe Seiyaku Co S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof.
DE19719817A1 (de) * 1997-05-13 1998-11-19 Hoechst Ag Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren

Also Published As

Publication number Publication date
MX9708343A (es) 1998-08-30
US6114529A (en) 2000-09-05
US7060832B2 (en) 2006-06-13
DE69736308T2 (de) 2007-06-14
KR100567957B1 (ko) 2006-04-05
DE69724081D1 (de) 2003-09-18
CA2533685A1 (fr) 1998-04-30
CN100473654C (zh) 2009-04-01
KR20060086818A (ko) 2006-08-01
KR100653592B1 (ko) 2006-12-05
HK1050356B (zh) 2007-01-19
CA2219692A1 (fr) 1998-04-30
US20030135049A1 (en) 2003-07-17
KR19980033318A (ko) 1998-07-25
CA2533685C (fr) 2009-05-26
SG88737A1 (en) 2002-05-21
KR100474496B1 (ko) 2005-09-30
EP0845464A2 (fr) 1998-06-03
CN1915995A (zh) 2007-02-21
DK1236728T3 (da) 2006-10-30
EP1236728B1 (fr) 2006-07-05
ATE332303T1 (de) 2006-07-15
EP1236728A2 (fr) 2002-09-04
EP0845464B1 (fr) 2003-08-13
US6015901A (en) 2000-01-18
TW464652B (en) 2001-11-21
ES2205134T3 (es) 2004-05-01
US6277992B1 (en) 2001-08-21
EP1236728A3 (fr) 2002-12-18
CA2219692C (fr) 2007-05-22
EP1528062A3 (fr) 2007-02-07
HK1011538A1 (en) 1999-07-16
KR100525025B1 (ko) 2005-10-31
EP1528062A2 (fr) 2005-05-04
HK1050356A1 (en) 2003-06-20
CN100528879C (zh) 2009-08-19
CN1183414A (zh) 1998-06-03
SG116433A1 (en) 2005-11-28
PT1236728E (pt) 2006-10-31
DE69736308D1 (de) 2006-08-17
KR100578779B1 (ko) 2006-05-12
SG103322A1 (en) 2004-04-29
ID18747A (id) 1998-05-07
SG104284A1 (en) 2004-06-21
CN1313286A (zh) 2001-09-19
ES2267879T3 (es) 2007-03-16
EP0845464A3 (fr) 1999-06-23
DK0845464T3 (da) 2003-12-01
US6716983B2 (en) 2004-04-06
US20020161231A1 (en) 2002-10-31
PT845464E (pt) 2003-12-31
US5932732A (en) 1999-08-03
ATE247120T1 (de) 2003-08-15
DE69724081T2 (de) 2004-06-09
US6388078B1 (en) 2002-05-14

Similar Documents

Publication Publication Date Title
CN1077109C (zh) S型2－取代羟基－2－中氮茚基丁酸酯化合物和其制备方法
CN1097054C (zh) 三环类吡唑衍生物及其组合物
CN1346358A (zh) 噻吩并嘧啶化合物及其盐和制备方法
WO2010027334A1 (fr) Nouveaux composés chiraux tricycliques et leur utilisation en catalyse asymétrique
CN1052979C (zh) 恩丹西酮的制备方法
CN1247562C (zh) 制备螺环季酮酸衍生物的方法
CN1642937A (zh) 制备手性1,4－二取代哌嗪的方法
CN1100094A (zh) 用于制备毒扁豆碱的中间体的对映选择性合成方法
CN1016869B (zh) 制备6，7-二酰基-7-脱乙酰福斯克林衍生物的新方法
CN1235880C (zh) 喹啉酮类衍生物及其可接受的盐，其制备方法、作为制备阿立哌唑的应用及阿立哌唑的制备方法
CN1171397A (zh) N－[(喹啉－2－基)苯基]磺酰胺晶体及其制备方法
CN1096297A (zh) 合成喜树碱和麦皮星以及它们的类似物和有关化合物的方法
CN112939848A (zh) 一种布比卡因及其中间体(s)-2-哌啶甲酸的制备方法
JPH10182646A (ja) Ｓ型２−置換ヒドロキシ−２−インドリジニル酪酸エステル誘導体及びその製法
CN1290247A (zh) 制备抗叶酸剂的方法和中间体
CN1869014A (zh) 制备坦舒乐欣及其相关的芳烷基胺衍生物的方法
CN85101580A (zh) 1，3-二氧六环衍生物的制备方法
JPS62205085A (ja) １−ベンジルオキシメチル−４−メチル−７，７−ジメチル−５，６，８−トリオキサ−９−オキソ−１，３，３ａ，４，５，６，７，８，９，９ｂ−デカヒドロナフト〔１，２−ｃ〕フランおよびその製造方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20020102

Termination date: 20091130